A final report from the Phase III METEOR trial makes a solid case that cabozantinib is a new standard of care in patients with advanced renal cell carcinoma (RCC) previously treated with antiangiogenic therapy.
Earlier reports from METEOR showed a progression-free survival (PFS) of 7.4 months with cabozantinib (Cabometyx, Exelixis) versus 3.9 months with everolimus (Afinitor, Novartis), for a hazard ratio of 0.51 (Clinical Oncology News Sept. 19, 2016; https://goo.gl/?CF6NWn). The latest report